Date Title Description PDF
27 Nov 2020 On business and financial situation The Company publishes the results of the PRISMA-3 study of the efficacy and safety of Doria® in schizophrenic patients in the journal npj Schizophrenia Download
09 Jul 2020 On business and financial situation ROVI informs on the Collaboration with Moderna for Outside the United States Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine Candidate Download

Pages

Date Title Description PDF
07 Mar 2024 On corporate transactions ROVI notes the recent press speculation and informs about the assessment of potential strategic alternatives  Download
01 Mar 2024 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 23 February and 29 February 2024 Download
27 Feb 2024 Annual Corporate Governance Report ROVI releases the 2023 Annual Corporate Governance Report Download
27 Feb 2024 Annual Report regarding remuneration of the members of the Board of Directors ROVI releases the 2023 annual report regarding remuneration of the members of the Board of Directors. Download
23 Feb 2024 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 16 February and 22 February 2024 Download

Pages

Date Title Description PDF
08 May 2019 Information on P&L ROVI releases the first quarter 2019 results presentation Download
08 May 2019 Information on P&L ROVI releases the press release related to the first quarter 2019 financial results Download
07 May 2019 Liquidity contracts and specialists ROVI announces the signature of a new liquidity contract with Renta 4 Banco, S.A.     Download
30 Apr 2019 Liquidity contracts and specialists ROVI announces the termination of the liquidity contract signed with JB Capital Markets, S.V., S.A.U.     Download
11 Apr 2019 Strategic agreements with third parties The Company releases the press release related to the marketing agreement of Tetridar® in Spain   Download

Pages